期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Tropifexor,a selective non-acid farnesoid X receptor agonist,improved nonalcoholic steatohepatitis in a phase 2 trial,but several issues remain to be resolved
1
作者 Masato Yoneda Takashi Kobayashi +4 位作者 Naohiro Wada Tomohiro Otani Asako Nogami Michihiro Iwaki Atsushi Nakajima 《Hepatobiliary Surgery and Nutrition》 SCIE 2023年第5期759-762,共4页
As obesity continues to escalate worldwide,nonalcoholic fatty liver disease(NAFLD)has emerged as the most prevalent form of liver disease,with a reported global prevalence of 30.1%(1).The prevalence of NAFLD,which was... As obesity continues to escalate worldwide,nonalcoholic fatty liver disease(NAFLD)has emerged as the most prevalent form of liver disease,with a reported global prevalence of 30.1%(1).The prevalence of NAFLD,which was around 25%in the 1990s,has been increasing year by year in recent years and has exceeded 35%in the past few years(1).The spectrum of disease includes nonalcoholic fatty liver(NAFL),characterized by macrovesicular hepatic steatosis that may be accompanied by mild inflammation,and nonalcoholic steatohepatitis(NASH),which is additionally characterized by the presence of inflammation and cellular injury(2). 展开更多
关键词 Nonalcoholic fatty liver disease(NAFLD) obesity nonalcoholic steatohepatitis(NASH) tropifexor selective non-acid farnesoid X receptor agonists(selective non-acid FXR agonists)
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部